Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 16FED 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Conditions

Colorectal Neoplasms 28Neoplasms 27Prostatic Neoplasms 16Lung Neoplasms 14Colonic Polyps 9Colonic Neoplasms 7Breast Neoplasms 7Pulmonary Disease, Chronic Obstructive 6Heart Failure 6Rare Diseases 4Liver Neoplasms 4Head and Neck Neoplasms 4Fibrosis 4Carcinoma, Hepatocellular 4Barrett Esophagus 4Urinary Incontinence 3Urinary Bladder Neoplasms 3Tobacco Use 3Pain 3Obesity 3Motor Activity 3Mental Disorders 3Lung Diseases 3Gastroesophageal Reflux 3Death 3Adenoma 3Uterine Cervical Neoplasms 2Smoking Cessation 2Sarcopenia 2Respiratory Tract Diseases 2

Interventions

Selective Serotonin Reuptake Inhibitors 1Methylphenidate 1Immunoglobulins 1Citalopram 1Amifampridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase NA × FED × Mental Disorders × Clear all
NCT00129467 2015-04-24

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

VA Office of Research and Development

Phase NA Completed
47 enrolled 13 charts

Caregiver Burden, Mental Disorders, Depression, Neoplasms, Pain

NCT00004682 2015-03-25

Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis

FDA Office of Orphan Products Development

Phase NA Terminated
100 enrolled

Mental Disorders, Myasthenia Gravis, Neurologic Manifestations, Rare Diseases

NCT00004832 2015-03-25

Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

FDA Office of Orphan Products Development

Phase NA Completed
26 enrolled

Mental Disorders, Neurologic Manifestations, Lambert-Eaton Myasthenic Syndrome, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡